Skip to main content
. 2019 Aug 14;105(4):1138–1146. doi: 10.3324/haematol.2019.227603

Figure 1.

Figure 1.

Comparison of outcomes in bone marrow (BM) patients without anti-thymocyte globulin (ATG) and in those given peripheral blood (PB) stem cells with ATG (the dotted line shows the PBSC with ATG curve adjusted for relevant covariates) in the cohort of patients receiving grafts from HLA-identical sibling donor (MSD). (A) Overall survival (OS), P=0.13. (B) Leukemia-free survival (LFS), P=0.065. (C) Incidence of relapse (RI), P=0.0496. (D) Non-relapse mortality (NRM), P=0.989. (E) chronic graft-versus-host disease (cGvHD), P=0.0186. (F) GvHD-free and relapse-free survival (GRFS), P=0.782.